Agnes I. Veldkamp

1.2k total citations
27 papers, 943 citations indexed

About

Agnes I. Veldkamp is a scholar working on Infectious Diseases, Virology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Agnes I. Veldkamp has authored 27 papers receiving a total of 943 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 15 papers in Virology and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Agnes I. Veldkamp's work include HIV/AIDS drug development and treatment (17 papers), HIV Research and Treatment (15 papers) and HIV-related health complications and treatments (8 papers). Agnes I. Veldkamp is often cited by papers focused on HIV/AIDS drug development and treatment (17 papers), HIV Research and Treatment (15 papers) and HIV-related health complications and treatments (8 papers). Agnes I. Veldkamp collaborates with scholars based in Netherlands, United States and Canada. Agnes I. Veldkamp's co-authors include Richard M. W. Hoetelmans, Jos H. Beijnen, Joep M. A. Lange, Jan W. Mulder, Pieter L. Meenhorst, Rolf P. G. van Heeswijk, Peter Reiss, Julio Montaner, David A. Cooper and David B. Hall and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Agnes I. Veldkamp

26 papers receiving 900 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Agnes I. Veldkamp Netherlands	17	697	510	185	140	118	27	943
Katy H. P. Moore United States	16	745 1.1×	393 0.8×	305 1.6×	120 0.9×	123 1.0×	24	1.1k
SH Khoo United Kingdom	15	614 0.9×	275 0.5×	200 1.1×	166 1.2×	123 1.0×	40	843
P. L. Meenhorst Netherlands	19	682 1.0×	355 0.7×	261 1.4×	134 1.0×	115 1.0×	37	1.1k
Patricia W. H. Hugen Netherlands	19	973 1.4×	733 1.4×	177 1.0×	172 1.2×	163 1.4×	27	1.1k
Kristel M. L. Crommentuyn Netherlands	16	661 0.9×	334 0.7×	154 0.8×	246 1.8×	105 0.9×	21	864
Deirdre Egan United Kingdom	15	730 1.0×	356 0.7×	199 1.1×	223 1.6×	137 1.2×	26	955
Gregory E. Chittick United States	15	484 0.7×	287 0.6×	198 1.1×	116 0.8×	90 0.8×	18	798
Daniel González de Requena Italy	18	742 1.1×	462 0.9×	247 1.3×	81 0.6×	163 1.4×	34	951
Brian L. Robbins United States	21	1.1k 1.6×	654 1.3×	397 2.1×	125 0.9×	154 1.3×	43	1.4k
Natsuo Tachikawa Japan	16	533 0.8×	217 0.4×	284 1.5×	66 0.5×	92 0.8×	74	999

Countries citing papers authored by Agnes I. Veldkamp

Since Specialization

Citations

This map shows the geographic impact of Agnes I. Veldkamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Agnes I. Veldkamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Agnes I. Veldkamp more than expected).

Fields of papers citing papers by Agnes I. Veldkamp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Agnes I. Veldkamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Agnes I. Veldkamp. The network helps show where Agnes I. Veldkamp may publish in the future.

Co-authorship network of co-authors of Agnes I. Veldkamp

This figure shows the co-authorship network connecting the top 25 collaborators of Agnes I. Veldkamp. A scholar is included among the top collaborators of Agnes I. Veldkamp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Agnes I. Veldkamp. Agnes I. Veldkamp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elbers, Paul, Matthijs R. A. Welkers, Agnes I. Veldkamp, et al.. (2023). Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients. Pharmaceutics. 15(1). 163–163. 15 indexed citations

Bos, Martine P., Agnes I. Veldkamp, Timo R. de Haan, et al.. (2023). Predicting treatment response to vancomycin using bacterial DNA load as a pharmacodynamic marker in premature and very low birth weight neonates: A population PKPD study. Frontiers in Pharmacology. 14. 1104482–1104482. 1 indexed citations

Vos, René, et al.. (2015). An UPLC–MS Detection Method for The Quantification of Five Antibiotics in Human Plasma. Bioanalysis. 7(18). 2321–2329. 11 indexed citations

Wilhelm, Abraham J., Jeroen C. G. den Burger, Otto Visser, et al.. (2013). Clinical Validation of Dried Blood Spot Sampling in Therapeutic Drug Monitoring of Ciclosporin A in Allogeneic Stem Cell Transplant Recipients. Therapeutic Drug Monitoring. 35(1). 92–95. 31 indexed citations

Sinjewel, Arno, Jeroen C. G. den Burger, René Vos, et al.. (2012). Rapid Quantification of Gabapentin, Pregabalin, and Vigabatrin in Human Serum by Ultraperformance Liquid Chromatography With Mass-Spectrometric Detection. Therapeutic Drug Monitoring. 35(1). 48–53. 29 indexed citations

Wilhelm, Abraham J., Peer de Graaf, Agnes I. Veldkamp, et al.. (2011). Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. British Journal of Clinical Pharmacology. 73(4). 553–563. 30 indexed citations

Graaf, Peer de, René Vos, Nanne K.H. de Boer, et al.. (2010). Limited stability of thiopurine metabolites in blood samples: Relevant in research and clinical practise. Journal of Chromatography B. 878(19). 1437–1442. 25 indexed citations

Boer, Nanne K.H. de, et al.. (2009). On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance. Current Drug Metabolism. 10(9). 981–997. 40 indexed citations

Maat, Monique M. R. de, Ron A. A. Mathôt, Agnes I. Veldkamp, et al.. (2002). HEPATOTOXICITY FOLLOWING NEVIRAPINE-CONTAINING REGIMENS IN HIV-1-INFECTED INDIVIDUALS. Pharmacological Research. 46(3). 295–300. 36 indexed citations

10.

Veldkamp, Agnes I., Rolf P. G. van Heeswijk, Jan W. Mulder, et al.. (2001). Limited Sampling Strategies for the Estimation of the Systemic Exposure to the HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Nevirapine. Therapeutic Drug Monitoring. 23(6). 606–611. 23 indexed citations

11.

Veldkamp, Agnes I., Jan‐Willem Mulder, Pieter L. Meenhorst, et al.. (2001). Saliva as an Alternative Body Fluid for Therapeutic Drug Monitoring of the Nonnucleoside Reverse Transcription Inhibitor Nevirapine. Therapeutic Drug Monitoring. 23(3). 255–258. 25 indexed citations

12.

Veldkamp, Agnes I., Jan W. Mulder, P. L. Meenhorst, et al.. (2001). Steady-State Pharmacokinetics of Twice-Daily Dosing of Saquinavir Plus Ritonavir in HIV-1–Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes. 27(4). 344–349. 42 indexed citations

13.

Veldkamp, Agnes I., Rolf P. G. van Heeswijk, Jan W. Mulder, et al.. (2001). Steady-State Pharmacokinetics of Twice-Daily Dosing of Saquinavir Plus Ritonavir in HIV-1–Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes. 27(4). 344–349. 10 indexed citations

14.

Heeswijk, Rolf P. G. van, Agnes I. Veldkamp, Jan W. Mulder, et al.. (2000). The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 14(8). F77–F82. 113 indexed citations

15.

Heeswijk, Rolf P. G. van, Agnes I. Veldkamp, Jan W. Mulder, et al.. (2000). Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study. AIDS. 14(9). F103–F110. 39 indexed citations

16.

Veldkamp, Agnes I., Rolf W. Sparidans, Richard M. W. Hoetelmans, & J. H. Beijnen. (1999). Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B Biomedical Sciences and Applications. 736(1-2). 123–128. 21 indexed citations

17.

Heeswijk, Rolf P. G. van, Agnes I. Veldkamp, Richard M. W. Hoetelmans, et al.. (1999). The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS. 13(14). F95–F99. 95 indexed citations

18.

Veldkamp, Agnes I., Richard M. W. Hoetelmans, J. H. Beijnen, Jan W. Mulder, & P. L. Meenhorst. (1999). Ritonavir Enables Combined Therapy with Rifampin and Saquinavir. Clinical Infectious Diseases. 29(6). 1586–1586. 49 indexed citations

19.

Veldkamp, Agnes I., Rolf P. G. van Heeswijk, Richard M. W. Hoetelmans, et al.. (1999). Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B Biomedical Sciences and Applications. 727(1-2). 151–157. 7 indexed citations

20.

Sparidans, Rolf W., Agnes I. Veldkamp, Richard M. W. Hoetelmans, & J. H. Beijnen. (1999). Improved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehyde. Journal of Chromatography B Biomedical Sciences and Applications. 736(1-2). 115–121. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact